摘要
目的探讨阿立哌唑对精神分裂症患者血清神经元特异性烯醇化酶(NSE)、S100B蛋白和髓鞘碱性蛋白(MBP)水平的影响及疗效。方法选取住院治疗的精神分裂症患者86例,将其随机分为观察组和对照组。观察组患者予以阿立哌唑片治疗,先予5 mg/次,1次/d,2周内逐渐增加剂量至维持量15 mg/d;对照组予以奥氮平片治疗,先予5 mg/次,1次/d,2周内逐渐增加剂量至维持量(10~20)mg/d。两组均连用12周。观察两组治疗前与治疗12周后血清MBP、S100B蛋白和NSE指标变化情况,并比较其效果和安全性。结果治疗12周后,两组患者血清NSE、S100B蛋白和MBP水平较前均有明显下降(P<0.05或P<0.01),且观察组患者下降幅度较对照组更明显(P<0.05);同时观察组患者临床总有效率明显优于对照组(P<0.05)。观察组TESS评分明显低于对照组[(3.12±0.54)分vs.(4.34±0.81)分,P<0.05]。结论阿立哌唑治疗精神分裂症疗效明显优于奥氮平,能明显改善其阳性和阴性症状,且不良作用更少,安全性更高,其作用机制可能与其能降低血清MBP、S100B蛋白和NSE指标及减轻中枢神经系统密切相关。
Objective To investigate the effect of aripiprazole on the levels of serum neuron-specific enolase （NSE）, SIOOB protein and myelin basic protein（MBP） in schizophrenic patients and its curative effect. Methods 86 patients with schizophrenia who were hospitalized in our hospital were randomly divided into observation group and control group. Patients in the observation group were given aripiprazole tablet, with initial dose of 5 rag, once a day. The dose was gradtially increased tO the maintenance dose of 15 mg/d; patients in the control group were given olanzapine taiJlets, With the initial dose of 5 mg, once a day. The dose was gradually increased to the maintenance dose of 10-20 mg/d. The administration was kept for 12 weeks in both groups. The changes of serum MBP, SIOOB protein and NSE were observed before treatment and 12 weeks after treatment in both groups, and its efficacy and safety were compared. Results After 12 weeks of treatment, serum NSE, S100B protein and MBP levels were significantly decreased in both groups compared with those before treatment（P〈0.05 or P〈0.01）, and the degree of decrease in the observation group was significantly higher than that in the control group（P〈0.05）; the total effective rate in the observation group was significantly better than that in the control group（P〈0.05）. The TESS score in the observation group was significantly lower than that in the control group [（3.12±0.54） points vs （4.34±0.81） points] （P〈0.05）. Conclusion Aripiprazole in the treatment of schizophrenia is significantly better than olanzapine, which can significantly improve its positive and negative symptoms, with less adverse effects and higher safety. Its mechanism may be closely related to its ability to reduce serum MBP, SIOOB protein and NSE, and alleviate the central nervous system,
作者
陈兴阳
许德河
贾方增
罗利飞
CHEN Xingyang XU Dehe JIA Fangzeng LUO Lifei(Department of Psychiatry, Taizhou Second People＇s Hospital in Zhejiang Province, Taizhou 317200, China Department of Pharmacy, Taizhou Second People＇s Hospital in Zhejiang Province, Taizhou 317200,China Department of Clinical Laboratory,Taizhou Second People＇s Hospital in Zhejiang Province, Taizhou 317200,China Department of Clinical Laboratory, Enze Hospital of Taizhou Enze Medical Center（Group）in Zhejiang Province,Taizhou 318050, China)
出处
《中国现代医生》
2017年第33期1-4,共4页
China Modern Doctor
基金
浙江省台州市科技局课题(1401ky18)
